These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 16892081)

  • 1. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer.
    King A; Selak MA; Gottlieb E
    Oncogene; 2006 Aug; 25(34):4675-82. PubMed ID: 16892081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations.
    Pollard PJ; Brière JJ; Alam NA; Barwell J; Barclay E; Wortham NC; Hunt T; Mitchell M; Olpin S; Moat SJ; Hargreaves IP; Heales SJ; Chung YL; Griffiths JR; Dalgleish A; McGrath JA; Gleeson MJ; Hodgson SV; Poulsom R; Rustin P; Tomlinson IP
    Hum Mol Genet; 2005 Aug; 14(15):2231-9. PubMed ID: 15987702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer?
    Laurenti G; Tennant DA
    Biochem Soc Trans; 2016 Aug; 44(4):1111-6. PubMed ID: 27528759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitochondrial tumour suppressors: a genetic and biochemical update.
    Gottlieb E; Tomlinson IP
    Nat Rev Cancer; 2005 Nov; 5(11):857-66. PubMed ID: 16327764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors.
    Xiao M; Yang H; Xu W; Ma S; Lin H; Zhu H; Liu L; Liu Y; Yang C; Xu Y; Zhao S; Ye D; Xiong Y; Guan KL
    Genes Dev; 2012 Jun; 26(12):1326-38. PubMed ID: 22677546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The TCA cycle and tumorigenesis: the examples of fumarate hydratase and succinate dehydrogenase.
    Pollard PJ; Wortham NC; Tomlinson IP
    Ann Med; 2003; 35(8):632-9. PubMed ID: 14708972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A role for mitochondrial enzymes in inherited neoplasia and beyond.
    Eng C; Kiuru M; Fernandez MJ; Aaltonen LA
    Nat Rev Cancer; 2003 Mar; 3(3):193-202. PubMed ID: 12612654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inactivation of SDH and FH cause loss of 5hmC and increased H3K9me3 in paraganglioma/pheochromocytoma and smooth muscle tumors.
    Hoekstra AS; de Graaff MA; Briaire-de Bruijn IH; Ras C; Seifar RM; van Minderhout I; Cornelisse CJ; Hogendoorn PC; Breuning MH; Suijker J; Korpershoek E; Kunst HP; Frizzell N; Devilee P; Bayley JP; Bovée JV
    Oncotarget; 2015 Nov; 6(36):38777-88. PubMed ID: 26472283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitochondria in cancer.
    Kroemer G
    Oncogene; 2006 Aug; 25(34):4630-2. PubMed ID: 16892077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of mutation of metabolism-related genes in genomic hypermethylation.
    Waterfall JJ; Killian JK; Meltzer PS
    Biochem Biophys Res Commun; 2014 Dec; 455(1-2):16-23. PubMed ID: 25111818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial dysfunctions in cancer: genetic defects and oncogenic signaling impinging on TCA cycle activity.
    Desideri E; Vegliante R; Ciriolo MR
    Cancer Lett; 2015 Jan; 356(2 Pt A):217-23. PubMed ID: 24614286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fumarate hydratase in cancer: A multifaceted tumour suppressor.
    Schmidt C; Sciacovelli M; Frezza C
    Semin Cell Dev Biol; 2020 Feb; 98():15-25. PubMed ID: 31085323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms.
    Schaefer IM; Hornick JL; Bovée JVMG
    Lab Invest; 2018 Apr; 98(4):414-426. PubMed ID: 29339836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting the TCA cycle: signaling to tumor formation.
    Raimundo N; Baysal BE; Shadel GS
    Trends Mol Med; 2011 Nov; 17(11):641-9. PubMed ID: 21764377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer. Puzzling patterns of predisposition.
    Pollard PJ; Ratcliffe PJ
    Science; 2009 Apr; 324(5924):192-4. PubMed ID: 19359573
    [No Abstract]   [Full Text] [Related]  

  • 16. Gerometabolites: the pseudohypoxic aging side of cancer oncometabolites.
    Menendez JA; Alarcón T; Joven J
    Cell Cycle; 2014; 13(5):699-709. PubMed ID: 24526120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct expression profile in fumarate-hydratase-deficient uterine fibroids.
    Vanharanta S; Pollard PJ; Lehtonen HJ; Laiho P; Sjöberg J; Leminen A; Aittomäki K; Arola J; Kruhoffer M; Orntoft TF; Tomlinson IP; Kiuru M; Arango D; Aaltonen LA
    Hum Mol Genet; 2006 Jan; 15(1):97-103. PubMed ID: 16319128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells.
    MacKenzie ED; Selak MA; Tennant DA; Payne LJ; Crosby S; Frederiksen CM; Watson DG; Gottlieb E
    Mol Cell Biol; 2007 May; 27(9):3282-9. PubMed ID: 17325041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warburg tumours and the mechanisms of mitochondrial tumour suppressor genes. Barking up the right tree?
    Bayley JP; Devilee P
    Curr Opin Genet Dev; 2010 Jun; 20(3):324-9. PubMed ID: 20304625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting cancer metabolism.
    Teicher BA; Linehan WM; Helman LJ
    Clin Cancer Res; 2012 Oct; 18(20):5537-45. PubMed ID: 23071355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.